We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





RapidRona Self-Collection COVID-19 Kit Secures FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 27 Nov 2020
Print article
Illustration
Illustration
RapidRona (Chicago, IL, USA) has received Emergency Use Authorization (EUA) from the FDA for its SARS-CoV-2 sample self-collection kit.

The kit aims to deliver convenience, ease-of-use, and guaranteed turnaround times for in vitro diagnostic testing for COVID-19 as the pandemic runs into flu season, testing shortages continue, and lead times among the largest testing labs increase. RapidRona leverages a growing network of dozens of independent CLIA-certified laboratories that want to help with the widely-criticized US testing shortage, but have no direct channel to do so. The EUA for the company’s Self-Collection Kit for COVID-19 samples allows it to initiate testing with these partners.

The kit and online interface were designed to take the effort out of getting tested by eliminating scheduling or lines, contact or observation, and “brain-tickling” deep nasal swabs. A patient-consumer can do a simple cotton swab of the nostrils in the comfort of their home, with contact-free pick-up and delivery to an authorized laboratory in RapidRona’s nation-wide network. The sample then undergoes RT-PCR - the current gold standard for diagnostic accuracy - and the results are electronically transmitted to the patient.

The EUA supports RapidRona’s first commercial efforts to match unmet demand to disconnected test capacity. The Self-Collection COVID-19 Kit will initially be made available online in the coming weeks for patients with symptoms or known exposure. Notification of kit availability will first be made to those on a waiting list, available at its website. When the online platform launches, the test is expected to retail for USD 200 which includes all shipping, handling and service fees.

“The investment of time and money to create a network that connects the disconnected laboratory capacity in the United States makes this the first EUA granted to a company built for adaptive matching of regional supply and demand during a pandemic. We offer CLIA-certified laboratories the opportunity to participate in the US testing effort as their capacity ebbs and flows. That flexibility to match lab supply with patient demand in real-time is what enables RapidRona to consistently deliver test results within 48 business hours of taking the sample.” said Heather Mlodinow, CEO and co-founder of RapidRona. “At the same time, our Self-Collection Kit allows the patient-consumer to remain safely tucked up at home, not being exposed nor exposing others to COVID-19.”

Related Links:
RapidRona

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.